fda and tirzepatide compounding September 2, 2025: U.S. restrictions have stemmed a flood of compounded semaglutide – Partnership for Safe Medicines Eli Lilly warns against compounding

The commercial success of GLP-1 receptor agonists such as Ozempic, Wegovy, and Rybelsus, along with dual GIP/GLP-1 receptor agonists including Mounjaro and Zepbound, has significantly increased the requirement for large-scale, high-quality peptide API manufacturing

The bottom line While there are no magic solutions to address the effects of GLP-1 medications, there are strategies to reduce bothersome effects

Step 3: Weight Care Consultation Take the next step toward your health goals

Neither compound interferes with the other

They want to see complaints, negative reviews, or concerns about side effects, refunds, or legitimacy